Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

770 - Avelumab in Newly Diagnosed Glioblastoma Multiforme - The SEJ Study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Immunotherapy

Tumour Site

Central Nervous System Malignancies

Presenters

Francois Jacques

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

F.H. Jacques1, G. Nicholas2, I. Lorimer3

Author affiliations

  • 1 Neurology, Clinique Neuro-Outaouais, J9J-0A5 - Gatineau/CA
  • 2 Oncology, Ottawa Hospital General campus, K1H-8L6 - Ottawa/CA
  • 3 Cancer Therapeutics Program, Ottawa Hospital Research Institute, K1H-8L6 - Ottawa/CA
More

Resources

Abstract 770

Background

Patients with Glioblastoma Multiforme (GBM) despite standard therapy have a dismal prognosis and thus represent a significant unmet medical need. GBM has well documented systemic and local immunosuppressive mechanisms to escape immune surveillance and grow. GBM tumor cells as well as the microglia within it have a high incidence of PD-L1 surface expression which makes it more susceptible to anti-PD-L1 antagonism and ADCC through avelumab therapy. Combination of avelumab with other anticancer therapies have been shown safe and perhaps synergistic. A clinical trial looking at adding avelumab to standard therapy in patients with GBM is therefore indicated.

Trial design

This is a single center, phase 2, open label, open-ended add-on, single dose study of 52 weeks duration in patients receiving standard therapy for newly diagnosed GBM. In total 30 patients who meet the entry criteria will be entered into the study within 3 weeks of finishing their last day of combined radiotherapy/temozolomide. Avelumab will be initiated concurrently with the initiation of the first 5 day, monthly cycle of temozolomide and continued for a total of 52 weeks. The study will consist of 3 different phases: Combination Phase a Monotherapy Phase and an Extended Safety Follow-up Phase.

Clinical trial identification

NCT03047473.

Legal entity responsible for the study

Clinique Neuro-Outaouais.

Funding

Study is funded by an unrestricted grant from Merck Serono.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.